^
    Back
    Association details:
    Biomarker:EGFR exon 19 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:erlotinib (EGFR inhibitor) +
    Cyramza (ramucirumab) (VEGFR-2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ESMO 2020
    Title:

    RELAY, erlotinib plus ramucirumab or placebo in untreated EGFR-mutated metastatic NSCLC: Outcomes by EGFR mutation type

    Published date:
    09/14/2020
    Excerpt:
    RAM+ERL-treated pts with ex21 mut had similar treatment benefit as pts with ex19 mut...These results support RAM+ERL as a first-line therapy for both ex19 and ex21-positive met NSCLC.
    Trial ID:
    RELAY
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) (RELAY)

    Excerpt:
    Eligible for first-line treatment with erlotinib based on documented evidence of tumor harboring an activating EGFR mutation [exon 19 deletion or exon 21 (L858R) substitution mutation].
    Trial ID:
    RELAY